DOP114 LDN-071, the novel amino acid-based PAI-1 inhibitor, significantly reduces the severity of acute and chronic inflammation in colitis models
Boldizsár Jójárt(University of Szeged), József Maléth(University of Szeged), Mária Bagyánszki(University of Szeged), Petra Pallagi(University of Szeged), Viktória Szabó(University of Szeged), Bence Pál Barta(University of Szeged), Gábor Heltovics(Io Therapeutics (United States)), Noémi Csákány-Papp(University of Szeged), Klaudia Farkas, H Laub(University of Szeged), István M. Mándity(Semmelweis University), L Kajári(University of Szeged), Béla Vasas(University of Szeged)
Cited by 0
Related Papers
Immunohistochemical analysis of neuron types in the mouse small intestine
|Cell and Tissue Research|2008|331
Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy
|Alimentary Pharmacology & Therapeutics|2020|80
New therapeutic targets in ulcerative colitis: The importance of ion transporters in the human colon
|Inflammatory Bowel Diseases|2010|77
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational study
|United European Gastroenterology Journal|2021|71
Diabetes-related alterations in the enteric nervous system and its microenvironment
|World Journal of Diabetes|2012|70